JP2007501257A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007501257A5 JP2007501257A5 JP2006522766A JP2006522766A JP2007501257A5 JP 2007501257 A5 JP2007501257 A5 JP 2007501257A5 JP 2006522766 A JP2006522766 A JP 2006522766A JP 2006522766 A JP2006522766 A JP 2006522766A JP 2007501257 A5 JP2007501257 A5 JP 2007501257A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- compound
- independently
- heteroatoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 27
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 125000005842 heteroatom Chemical group 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 239000001301 oxygen Substances 0.000 claims 7
- 239000011593 sulfur Substances 0.000 claims 7
- -1 wherein in Inorganic materials 0.000 claims 7
- 125000003386 piperidinyl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 208000018706 hematopoietic system disease Diseases 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 3
- 210000000214 mouth Anatomy 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 2
- 208000019838 Blood disease Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000001118 alkylidene group Chemical group 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 210000002429 large intestine Anatomy 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 claims 1
- 206010073069 Hepatic cancer Diseases 0.000 claims 1
- 206010023347 Keratoacanthoma Diseases 0.000 claims 1
- 241000023320 Luma <angiosperm> Species 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 229910003850 O-nPr Inorganic materials 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 210000003445 biliary tract Anatomy 0.000 claims 1
- 201000001531 bladder carcinoma Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 239000000284 extract Substances 0.000 claims 1
- 210000003608 fece Anatomy 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000002768 hair cell Anatomy 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000003849 large cell carcinoma Diseases 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000000088 lip Anatomy 0.000 claims 1
- 201000002250 liver carcinoma Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 201000010174 renal carcinoma Diseases 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000000582 semen Anatomy 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
- 210000002105 tongue Anatomy 0.000 claims 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 claims 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- NWMSEIUNINGHKY-UHFFFAOYSA-N C(C1)C1[n]1nc(Nc2cc(-c3ccccc3)cc(-c3ccccc3)n2)nc1 Chemical compound C(C1)C1[n]1nc(Nc2cc(-c3ccccc3)cc(-c3ccccc3)n2)nc1 NWMSEIUNINGHKY-UHFFFAOYSA-N 0.000 description 1
- SLMLXJIQCXERGF-UHFFFAOYSA-N CC(C)(c1cc(Nc2n[n](C3CC3)cn2)ccc1)Oc1cc(Cl)ccc1 Chemical compound CC(C)(c1cc(Nc2n[n](C3CC3)cn2)ccc1)Oc1cc(Cl)ccc1 SLMLXJIQCXERGF-UHFFFAOYSA-N 0.000 description 1
- WGVPGORHWKZTPU-UHFFFAOYSA-N CN(CC1)CCN1c1nc(-c2ccccc2)nc(Nc2n[n](C3CC3)cn2)c1 Chemical compound CN(CC1)CCN1c1nc(-c2ccccc2)nc(Nc2n[n](C3CC3)cn2)c1 WGVPGORHWKZTPU-UHFFFAOYSA-N 0.000 description 1
- UCTZIHOXMNMFQW-UHFFFAOYSA-N Cc1ccc(-c2cnc[o]2)c(OC)c1 Chemical compound Cc1ccc(-c2cnc[o]2)c(OC)c1 UCTZIHOXMNMFQW-UHFFFAOYSA-N 0.000 description 1
- UYLUNGSLZLSLGL-UHFFFAOYSA-N N#Cc(cc1)ccc1Sc1cc(Nc2n[n](C3CC3)cn2)c2[nH]cnc2c1 Chemical compound N#Cc(cc1)ccc1Sc1cc(Nc2n[n](C3CC3)cn2)c2[nH]cnc2c1 UYLUNGSLZLSLGL-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49278703P | 2003-08-06 | 2003-08-06 | |
| US60/492,787 | 2003-08-06 | ||
| PCT/US2004/025539 WO2005013982A1 (en) | 2003-08-06 | 2004-08-06 | Aminotriazole compounds useful as inhibitors of protein kinases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007501257A JP2007501257A (ja) | 2007-01-25 |
| JP2007501257A5 true JP2007501257A5 (cg-RX-API-DMAC10.html) | 2007-09-13 |
| JP4889489B2 JP4889489B2 (ja) | 2012-03-07 |
Family
ID=34135157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006522766A Expired - Fee Related JP4889489B2 (ja) | 2003-08-06 | 2004-08-06 | プロテインキナーゼのインヒビターとして有用なアミノトリアゾール化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7226920B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1663211B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP4889489B2 (cg-RX-API-DMAC10.html) |
| AR (1) | AR045731A1 (cg-RX-API-DMAC10.html) |
| AT (1) | ATE455546T1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2004263148B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2534921C (cg-RX-API-DMAC10.html) |
| DE (1) | DE602004025258D1 (cg-RX-API-DMAC10.html) |
| PE (1) | PE20050338A1 (cg-RX-API-DMAC10.html) |
| TW (1) | TW200514776A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2005013982A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| ES2421139T3 (es) | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
| ATE455546T1 (de) * | 2003-08-06 | 2010-02-15 | Vertex Pharma | Aminotriazol-verbindungen als proteinkinase- hemmer |
| JP2007522233A (ja) | 2004-02-11 | 2007-08-09 | アムジエン・インコーポレーテツド | バニロイド受容体リガンド及び治療におけるそれらの使用 |
| PT1791830E (pt) | 2004-09-17 | 2011-04-04 | Vertex Pharma | Compostos de diaminotriazole úteis como inibidores de proteína-quinase |
| PL1811998T3 (pl) | 2004-10-21 | 2011-05-31 | Vertex Pharma | Triazole użyteczne jako inhibitory kinaz białkowych |
| CN100334084C (zh) * | 2005-04-26 | 2007-08-29 | 武汉大学 | 联三唑化合物及其制备方法和用途 |
| EP1896134A2 (en) | 2005-06-13 | 2008-03-12 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
| WO2007013830A1 (en) | 2005-07-26 | 2007-02-01 | Portela & Ca. S.A. | Nitrocatechol derivatives as comt inhibitors |
| US7345178B2 (en) * | 2005-08-04 | 2008-03-18 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| CA2621503C (en) | 2005-09-07 | 2014-05-20 | Rigel Pharmaceuticals, Inc. | Triazole derivatives useful as axl inhibitors |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| CA2663856A1 (en) | 2006-09-28 | 2008-04-10 | Exelixis, Inc. | Jak-2 modulators and methods of use |
| AU2007305016B2 (en) | 2006-10-02 | 2011-11-03 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
| PL2848610T3 (pl) * | 2006-11-15 | 2018-01-31 | Ym Biosciences Australia Pty | Inhibitory aktywności kinazy |
| KR20090092317A (ko) * | 2006-12-11 | 2009-08-31 | 아이알엠 엘엘씨 | 키나제 억제제로서의 화합물 및 조성물 |
| ES2406930T3 (es) | 2006-12-29 | 2013-06-10 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos con arilo bicíclico y heteroarilo bicíclico útiles como inhibidores de AXL |
| RS53281B (sr) | 2006-12-29 | 2014-08-29 | Rigel Pharmaceuticals Inc. | Policiklični heteroaril supstituisani triazoli koji su korisni kao axl inhibitori |
| CA2710051C (en) | 2006-12-29 | 2017-05-16 | Rigel Pharmaceuticals, Inc. | Substituted triazoles useful as axl inhibitors |
| CN101622248B (zh) | 2006-12-29 | 2013-04-17 | 里格尔制药公司 | 用作axl抑制剂的n3-杂芳基取代的三唑和n5-杂芳基取代的三唑 |
| CA2710230C (en) | 2006-12-29 | 2016-02-23 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| DK2481410T3 (en) | 2007-01-31 | 2016-10-24 | Bial - Portela & Ca S A | Nitrocatecholderivater as COMT inhibitors administered in a specific dosage regimen |
| CA2704052C (en) | 2007-10-26 | 2015-04-21 | Rigel Pharmaceuticals, Inc. | Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| BRPI0908731A2 (pt) | 2008-03-17 | 2017-05-16 | Bial - Portela & C A S A | formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-óxi-piridina-3-il)[1,2,4]oxadiazol-5-il]-3-nitrobenzeno-1,2-diol |
| CA2730251C (en) | 2008-07-09 | 2016-08-09 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| CA2730231C (en) | 2008-07-09 | 2016-10-18 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| WO2010078258A1 (en) * | 2008-12-29 | 2010-07-08 | The Board Of Trustees Of The University Of Alabama | Compounds comprising two or more biologically functional ions and method of treating parkinson's disease |
| BRPI1007046B1 (pt) | 2009-01-16 | 2019-07-16 | Rigel Pharmaceuticals, Inc. | Inibidores axl para uso em terapia de combinação para evitar, tratar ou controlar o câncer metastático. |
| CN102448444B (zh) | 2009-04-01 | 2016-05-25 | 巴尔-波特拉及康邦亚股份有限公司 | 包括硝基儿茶酚衍生物的药物制剂及其制备方法 |
| WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
| LT2496567T (lt) | 2009-11-05 | 2017-11-27 | Rhizen Pharmaceuticals S.A. | Nauji benzopirano kinazės moduliatoriai |
| BR112012029647A2 (pt) | 2010-05-21 | 2016-08-02 | Chemilia Ab | novos derivados de pirimidinas |
| JP2012102090A (ja) * | 2010-10-15 | 2012-05-31 | Sumitomo Chemical Co Ltd | ピリミジン化合物およびその有害生物防除用途 |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| MX2013010898A (es) | 2011-03-24 | 2013-12-06 | Chemilia Ab | Novedoso derivados de la pirimidina. |
| PT2705029T (pt) | 2011-05-04 | 2019-02-01 | Rhizen Pharmaceuticals S A | Novos compostos como moduladores de proteína quinases |
| CN102827073A (zh) * | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN103030646B (zh) * | 2011-09-29 | 2016-08-24 | 上海恒瑞医药有限公司 | 苯并二氧六环类衍生物、其制备方法及其在医药上的应用 |
| US9126988B2 (en) | 2011-12-13 | 2015-09-08 | Bial—Portela & Ca, S.A. | Intermediate for preparing a catechol-O-methyltransferase inhibitor |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| WO2013106614A1 (en) * | 2012-01-13 | 2013-07-18 | Bristol-Myers Squibb Company | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| US20150182490A1 (en) | 2012-06-26 | 2015-07-02 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| PT2870157T (pt) | 2012-07-04 | 2017-11-27 | Rhizen Pharmaceuticals S A | Inibidores seletivos de delta pi3k |
| WO2014110200A1 (en) | 2013-01-10 | 2014-07-17 | Zisman Lawrence S | Non-selective kinase inhibitors |
| WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CN105593215B (zh) | 2013-07-11 | 2019-01-15 | 安吉奥斯医药品有限公司 | 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物 |
| WO2015010297A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| ES2959419T3 (es) | 2013-10-11 | 2024-02-26 | Pulmokine Inc | Formulaciones secas por aspersión |
| PH12021551647A1 (en) | 2014-03-14 | 2022-06-06 | Agios Pharmaceuticals Inc | Pharmaceutical compositions of therapeutically active compounds |
| WO2016083863A1 (en) | 2014-11-28 | 2016-06-02 | Bial - Portela & Ca, S.A. | Medicaments for slowing parkinson's disease |
| US10118904B2 (en) | 2015-06-05 | 2018-11-06 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of Demyelinating Diseases |
| MD3362066T2 (ro) | 2015-10-15 | 2022-08-31 | Les Laboratoires Servier Sas | Terapie combinată pentru tratamentul tumorilor maligne |
| HUE067449T2 (hu) | 2015-10-15 | 2024-10-28 | Servier Lab | Ivozidenib, citarabin és daunorubicin vagy idarubicin kombinációs terápa akut mielogén leukémia kezelésére |
| AU2017251537B2 (en) | 2016-04-15 | 2020-10-08 | Abbvie Inc. | Bromodomain inhibitors |
| RU2763525C2 (ru) | 2016-10-27 | 2021-12-30 | Пульмокин, Инк. | Комбинированная терапия для лечения легочной гипертензии |
| WO2018106646A1 (en) * | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
| US10617680B2 (en) * | 2017-04-18 | 2020-04-14 | Celgene Quanticel Research, Inc. | Therapeutic compounds |
| GB201801226D0 (en) * | 2018-01-25 | 2018-03-14 | Redx Pharma Plc | Modulators of Rho-associated protein kinase |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8429307D0 (en) * | 1984-11-20 | 1984-12-27 | Shell Int Research | Heterocyclic herbicides |
| US5801031A (en) * | 1996-04-05 | 1998-09-01 | Health Research, Incorporated | Human and rat gamma glutamyl hydrolase genes |
| SK6652000A3 (en) * | 1997-11-11 | 2002-05-09 | Pfizer Prod Inc | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| ES2221426T3 (es) * | 1998-08-20 | 2004-12-16 | Smithkline Beecham Corporation | Nuevos compuestos de triazol sustituidos. |
| AU764479B2 (en) * | 1998-10-29 | 2003-08-21 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme |
| US6596747B2 (en) * | 1998-10-29 | 2003-07-22 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same |
| US6124272A (en) * | 1999-04-09 | 2000-09-26 | Isis Pharmaceutical Inc. | Antisense modulation of PDK-1 expression |
| FR2802530B1 (fr) * | 1999-12-17 | 2002-02-22 | Sanofi Synthelabo | Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant |
| AU2001290912A1 (en) * | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| NZ526624A (en) * | 2000-12-22 | 2005-07-29 | Ortho Mcneil Pharm Inc | Substituted triazole diamine derivatives as kinase inhibitors |
| DE10123586A1 (de) * | 2001-05-08 | 2002-11-28 | Schering Ag | 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren |
| US6846928B2 (en) | 2002-03-15 | 2005-01-25 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| ATE455546T1 (de) * | 2003-08-06 | 2010-02-15 | Vertex Pharma | Aminotriazol-verbindungen als proteinkinase- hemmer |
-
2004
- 2004-08-06 AT AT04780381T patent/ATE455546T1/de not_active IP Right Cessation
- 2004-08-06 AR ARP040102824A patent/AR045731A1/es unknown
- 2004-08-06 PE PE2004000768A patent/PE20050338A1/es not_active Application Discontinuation
- 2004-08-06 AU AU2004263148A patent/AU2004263148B2/en not_active Ceased
- 2004-08-06 JP JP2006522766A patent/JP4889489B2/ja not_active Expired - Fee Related
- 2004-08-06 CA CA2534921A patent/CA2534921C/en not_active Expired - Fee Related
- 2004-08-06 US US10/914,051 patent/US7226920B2/en not_active Expired - Fee Related
- 2004-08-06 EP EP04780381A patent/EP1663211B1/en not_active Expired - Lifetime
- 2004-08-06 DE DE602004025258T patent/DE602004025258D1/de not_active Expired - Lifetime
- 2004-08-06 WO PCT/US2004/025539 patent/WO2005013982A1/en not_active Ceased
- 2004-08-06 TW TW093123755A patent/TW200514776A/zh unknown
-
2007
- 2007-04-13 US US11/787,165 patent/US7598245B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113717156B (zh) | Egfr抑制剂、其制备方法及用途 | |
| DE60114215T2 (de) | Kondensierte pyrrolocarbazole gegen entzündungen | |
| TW202144338A (zh) | 嘧啶并二環類衍生物、其製備方法及其在醫藥上的應用 | |
| US20130131068A1 (en) | Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof | |
| WO2005035516A1 (ja) | 新規縮合複素環化合物およびその用途 | |
| EP2616461A2 (en) | Potent and selective inhibitors of hepatitis c virus | |
| HU223666B1 (hu) | Taxoidok, előállításuk és ezeket tartalmazó gyógyszerkészítmények | |
| WO2020142413A1 (en) | Compositions and methods for modulating hair growth | |
| JP2007530595A5 (cg-RX-API-DMAC10.html) | ||
| JP2006523202A (ja) | 生体還元により活性化されるプロドラッグ | |
| TWI923600B (zh) | 含硫異吲哚啉類衍生物、其製備方法及其在醫藥上的應用 | |
| Zhou et al. | Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC | |
| JP2019520367A (ja) | 新規なヘテロサイクリック誘導体化合物およびその用途 | |
| KR20060017763A (ko) | 치료에 사용하는 아제티딘카르복스아미드 유도체의 용도 | |
| CN113825757B (zh) | 取代的稠合双环类衍生物、其制备方法及其在医药上的应用 | |
| HU229937B1 (hu) | Kondenzált azepinek mint vazopresszin agonisták, a vegyületek vagy ezek gyógyászatilag elfogadható sóinak alkalmazása gyógyszer-készítmény komponenseként vagy ennek elõállítására és a hatóanyagot tartalmazó gyógyszerkészítmény | |
| US8895602B1 (en) | 6-pyrazolylamido-3-substituted azabicyclo[3.1.0]hexane compounds as calcium channel inhibitors | |
| ES2279452T3 (es) | 6-((sustituido)fenil)triazolopirimidinas como agentes antineoplasicos. | |
| EP1847534B1 (en) | Thiadiazoline derivatives for treating cancer | |
| RU2007134970A (ru) | Производные пирролидинацетилена и пиперидинацетилена для применения в качестве антагонистов mglur5 | |
| ES2740428T3 (es) | Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de la elastasa de neutrófilos | |
| US9221799B2 (en) | Anti-cancer agents | |
| CN118271307A (zh) | Prmt5-mta抑制剂 | |
| CN106554314A (zh) | 苯甲酰胺类衍生物 | |
| RU2006122935A (ru) | Новые производные бензимидазола и имидазопиридина и их применение в качестве лекарственных средств |